Despite the fact that multiple experimental studies have demonstrated that sTNFR2 can reduce inflammation by effectively competing with transmembrane TNFR2 in terms of their binding ability to TNF-α [167], the notion that sTNFR2 causes inflammation and other cancer-related problems in BC patients must be revised to account for this fact when designing clinical trials in the feature. Here, TNF is linked to cancer.